Skip to main content

Table 2 Pharmacokinetic parameters of rh-HGF

From: Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

parameters

Estimate values

95% confidence interval

Day 1

   

Cmax (ng/mL)

18.8

13.0

24.7

AUC0-300 (ng/mL*min)

1485.6

991.3

1979.8

AUC0-∞ (ng/mL*min)

1994.0

1214.6

2773.3

T1/2 (min)

756.2

526.8

985.7

CL (mL/m2/min)

0.000361

0.000160

0.000561

Vdss (mL/m2)

0.125

0.063

0.186

Day 5

   

Cmax (ng/mL)

21.3

12.8

29.9

AUC0-300 (ng/mL*min)

1727.2

1099.7

2354.7

AUC0-∞ (ng/mL*min)

2493.8

1647.0

3340.5

T1/2 (min)

843.6

540.5

1146.6

CL (mL/m2/min)

0.000277

0.000138

0.000416

Vdss (mL/m2)

0.106

0.059

0.153

Day 11

   

Cmax (ng/mL)

22.3

11.4

33.1

AUC0-300 (ng/mL*min)

1965.5

801.6

3129.5

AUC0-∞ (ng/mL*min)

3126.4

1355.2

4897.5

T1/2 (min)

633.3

318.0

948.6

CL (mL/m2/min)

0.000230

0.000095

0.000365

Vdss (mL/m2)

0.088

0.031

0.146